Welcome to our dedicated page for Karyopharm Therapeutics SEC filings (Ticker: KPTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Karyopharm Therapeutics pioneered selinexor to block nuclear export; now its SEC reports are the next puzzle. Every 10-K outlining XPOVIO revenue, each 10-Q updating trial enrolment, and the swift 8-K announcing FDA designations hit EDGAR fast—yet remain locked in technical jargon. If you have ever searched “Karyopharm Therapeutics SEC filings explained simply” or asked, “How do I read a Karyopharm Therapeutics quarterly earnings report 10-Q filing?” you know the challenge of turning dense biotech disclosures into actionable insight.
Stock Titan solves that challenge with AI-powered analysis. Our engine reads every page the moment it’s filed, highlights new risk-factor language and converts tables into plain English. Want alerts for “Karyopharm Therapeutics insider trading Form 4 transactions” or “Karyopharm Therapeutics executive stock transactions Form 4”? We push them in real time, complete with context. Prefer the long view? Each upload arrives with an AI summary that makes a “Karyopharm Therapeutics annual report 10-K simplified.”
Investors following drug development need specifics: cash burn, partnership milestones, clinical data triggers. In the 10-Q we flag R&D spend by trial; the DEF 14A delivers “Karyopharm Therapeutics proxy statement executive compensation” comparisons; and our feed labels every “Karyopharm Therapeutics 8-K material events explained” link. Add “Karyopharm Therapeutics earnings report filing analysis,” Form S-3 shelf registrations, and “Karyopharm Therapeutics Form 4 insider transactions real-time,” and you have one searchable workspace—powered by AI—to understand the company before the market does.
Karyopharm Therapeutics (KPTI) reported an insider equity grant: EVP, CFO & Treasurer Lori Macomber received 43,650 restricted stock units (RSUs) on 10/15/2025 at a price of $0. The RSUs convert into common stock on a one-for-one basis and vest 100% on December 31, 2026. Following the award, her beneficial ownership stands at 54,316 shares. The reported share amounts reflect the company’s one‑for‑fifteen reverse stock split effected on February 25, 2025.
Karyopharm Therapeutics (KPTI) reported an executive equity award on a Form 4. EVP & Chief Commercial Officer Sohanya Cheng received 43,650 restricted stock units (RSUs) on 10/15/2025 at $0. The RSUs convert into common stock on a one-for-one basis and vest 100% on December 31, 2026. Following the award, Ms. Cheng beneficially owns 79,506 shares directly.
Karyopharm Therapeutics (KPTI) reported an officer equity grant. SVP, General Counsel & Secretary Michael Mano received 43,650 restricted stock units (RSUs) on 10/15/2025 at a price of $0. Each RSU converts into one share of common stock and vests 100% on December 31, 2026. Following the award, the reporting person beneficially owned 65,075 shares directly.
Karyopharm Therapeutics (KPTI) reported an insider equity award for its President and CEO, Richard Paulson, on 10/15/2025. He received 114,285 restricted stock units at $0 under the company’s 2022 Equity Incentive Plan. The RSUs convert into common stock on a one-for-one basis and vest 100% on December 31, 2026. Following the grant, Paulson’s beneficial ownership totaled 198,331 common shares, held directly. He is also listed as a director.
Karyopharm Therapeutics (KPTI) reported an insider equity grant on a Form 4. EVP, Chief Development Officer Stuart Poulton received 39,682 restricted stock units (RSUs) on 10/15/2025 under the company’s 2022 Equity Incentive Plan at a reported price of $0. The RSUs convert to common stock on a one‑for‑one basis and vest 100% on December 31, 2026.
Following the grant, his direct beneficial ownership was 67,392 shares. This filing documents a routine equity award to a company officer.
Karyopharm Therapeutics (KPTI)12,799 restricted stock units (RSUs) on October 15, 2025 at a stated price of $0. The RSUs convert into common stock on a one-for-one basis.
According to the award terms, 2,799 RSUs vest in two equal annual installments beginning October 31, 2026, and 10,000 RSUs vest 100% on October 15, 2026. Following this award, Abate beneficially owned 22,845 shares, reported as Direct (D) ownership.
Karyopharm Therapeutics (KPTI) completed a set of financing transactions. The company issued 9.00% senior secured convertible notes in two series: $15.0 million aggregate principal amount due 2028 and $103.5 million aggregate principal amount due 2029. It also borrowed $12.5 million under its existing credit and guaranty agreement.
The company entered into indentures for each note series with Wilmington Savings Fund Society as trustee and collateral agent and executed related registration rights agreements with term loan lenders. Exhibits include a first amendment and waiver to the credit agreement, a note purchase agreement, exchange agreements, warrant forms, a pre-funded warrant form, and a sixth amendment to the revenue interest financing agreement.
Shares outstanding were 15,926,939 as of October 14, 2025, assuming no exercise of pre-funded warrants or warrants and no conversions of the new convertible notes.
Karyopharm Therapeutics, Inc. disclosed an amendment and related licensing activity centered on its oncology drug selinexor. Under an Amendment No. 4 dated
Karyopharm Therapeutics (KPTI) reported an insider transaction by its Chief Accounting Officer, Kristin Abate. On 10/01/2025, Abate sold 362 shares of common stock at a weighted average price of $6.296. Following the sale, she beneficially owned 10,046 shares directly.
According to the filing, the broker-assisted sale was executed under a durable automatic sale instruction plan adopted on May 27, 2021, to satisfy withholding taxes upon the vesting of PSUs, and does not represent a discretionary trade.
Richard A. Paulson, President, CEO and a director of Karyopharm Therapeutics (KPTI), reported the vesting of 2,800 performance-based restricted stock units (PSUs) on September 12, 2025. These PSUs were granted in February 2023 and were earned after the Compensation Committee certified completion of enrollment in the company’s Phase 3 SENTRY trial; each earned PSU represents the contingent right to one share and vested upon certification. Following vesting, a broker-assisted sale executed under an automatic sale instruction plan sold 1,257 shares on September 15, 2025 at $6.43 per share to satisfy withholding tax obligations. After these transactions, the reporting person beneficially owned 84,046 shares.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
